ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,805.42
0.62%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Reata Pharmaceuticals Inc (RETA)

  7. Reata Pharmaceuticals Inc (RETA) Noticias

RETA Reata Pharmaceuticals Inc

172.36
0.00 (0.00%)
25 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Reata Pharmaceuticals Inc RETA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 172.36 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
172.36 172.36
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
06/10/202315:07EDGAR2Form 15-12G - Securities registration termination [Section..
28/9/202315:30EDGAR2Form SC 13D/A - General statement of acquisition of..
26/9/202318:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202316:25EDGAR2Form 8-K - Current report
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:25EDGAR2Form POSASR - Post-effective Amendment to an automatic shelf..
26/9/202315:23EDGAR2Form S-8 POS - Securities to be offered to employees in..
26/9/202307:59GLOBEBiogen Completes Acquisition of Reata Pharmaceuticals
21/9/202315:05EDGAR2Form 8-K - Current report
21/9/202309:08BWReata Pharmaceuticals Stockholders Approve Merger..
18/9/202316:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/9/202315:26EDGAR2Form 144 - Report of proposed sale of securities
12/9/202312:20EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
12/9/202312:16EDGAR2Form 8-K - Current report
07/9/202315:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202315:09EDGAR2Form 144 - Report of proposed sale of securities
05/9/202315:08EDGAR2Form 144 - Report of proposed sale of securities
22/8/202307:00EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
17/8/202315:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202315:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202315:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202315:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202316:04EDGAR2Form 144 - Report of proposed sale of securities
16/8/202316:03EDGAR2Form 144 - Report of proposed sale of securities
16/8/202315:55EDGAR2Form 144 - Report of proposed sale of securities
16/8/202315:54EDGAR2Form 144 - Report of proposed sale of securities
16/8/202315:53EDGAR2Form 144 - Report of proposed sale of securities
15/8/202318:38EDGAR2Form 144 - Report of proposed sale of securities
15/8/202318:32EDGAR2Form 144 - Report of proposed sale of securities
15/8/202318:12EDGAR2Form 144 - Report of proposed sale of securities
11/8/202315:38EDGAR2Form PREM14A - Preliminary proxy statements relating to..
01/8/202316:17EDGAR2Form SC 13D/A - General statement of acquisition of..
01/8/202315:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202315:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202315:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202315:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/7/202306:20IHMARKETNEWSMonday’s Wall Street Highlights: Palantir Technologies,..
31/7/202306:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
31/7/202306:01EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
RETA
Reata Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados